Illumina, Inc. (NASDAQ:ILMN) Stock Has Average Target Price of $238.53 According to Analysts

Key Points

• Analysts have a neutral overall view of Illumina: Nineteen analysts assign the stock an average “Hold” rating, with nine buys, seven holds and three sells. The average 12-month price target is $238.53, close to the reported share price of $235.99.
• Recent results exceeded earnings expectations. Illumina reported quarterly EPS above consensus and 4.2% year-over-year revenue growth, while management raised its full-year outlook, citing clinical sequencing demand and adoption of the NovaSeq X platform.
• Investors still face several risks, including China-related challenges, tariffs, weaker research-market demand and pricing pressure. Analyst sentiment has become more cautious, with JPMorgan recently lowering its price target, while insiders have sold significant amounts of stock over the past 90 days.

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have received an average rating of "Hold" from the nineteen analysts that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $238.53.

ILMN has been the subject of several research reports. Argus upped their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a research report on Thursday, September 3rd. Royal Bank Of Canada raised their price target on Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a research report on Monday, October 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Illumina in a research note on Monday, August 31st. Canaccord Genuity Group upped their price objective on Illumina from $205.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, October 19th. Finally, UBS Group upgraded Illumina from a "neutral" rating to a "buy" rating and increased their price objective for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th.

Illumina Stock Performance

NASDAQ ILMN opened at $235.99 on Friday. Illumina has a 52-week low of $106.12 and a 52-week high of $309.35. The company has a 50-day simple moving average of $249.30 and a 200 day simple moving average of $176.18. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The company has a market capitalization of $35.63 billion, a PE ratio of 40.62, a price-to-earnings-growth ratio of 3.34 and a beta of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.34 EPS. On average, research analysts predict that Illumina will post 5.43 EPS for the current year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Illumina in the second quarter worth about $3,374,423,000. WCM Investment Management LLC grew its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the period. Primecap Management Co. CA purchased a new position in shares of Illumina during the 2nd quarter worth approximately $617,981,000. Janus Henderson Group PLC grew its holdings in shares of Illumina by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company's stock worth $258,924,000 after acquiring an additional 29,094 shares during the period. Finally, Southpoint Capital Advisors LP raised its position in shares of Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company's stock worth $258,846,000 after acquiring an additional 349,536 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.